Pulmonary tuberculosis
Conditions
Interventions
Experimental Group (Contezoleam Group):HREC (Isoniazid, Rifampicin, Ethambutol, Contezoleam)
Control Group (Pyrazinamide Group):HREZ (Isoniazid, Rifampicin, Ethambutol, Pyrazinamide)
Sponsors
Shanghai Public Health Clinical Center
Eligibility
Sex/Gender
All
Age
60 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Age between 60 and 85 years, regardless of gender; 2.Diagnosed with pulmonary tuberculosis confirmed by WHO bacteriological criteria, with no evidence of resistance to first-line anti-tuberculosis drugs (at least confirmed sensitivity to rifampicin); 3.No prior anti-tuberculosis treatment before enrollment, or exposure to anti-tuberculosis drugs for less than one week; 4.Able to understand and sign the informed consent form, comply with medication, testing, and follow-up during the study, and promptly report adverse events.
Exclusion criteria
Exclusion criteria: 1.Allergy to any of the anti-tuberculosis drugs used in the study regimen or a history of allergy to such drugs; 2.Participation in any other clinical trial (in vivo) within the past three months; 3.Co-infection with non-tuberculous mycobacteria; 4.Other conditions deemed by the investigator as unsuitable for participation in this trial (including any situation where first-line treatment is not appropriate).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment Success Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Microbiological conversion rate, incidence of adverse events, and rate of acquired drug resistance;Adverse events; | — |
Countries
China
Contacts
Public ContactXia Lu
Shanghai Public Health Clinical Center
Outcome results
None listed